Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of Guelph
$60,000.00
Investigating the role of ShcD signaling in metastatic breast cancer
EF 2020-21
Résumé
Breast cancer is the most frequently diagnosed cancer worldwide and it is responsible for more female deaths than any other cancer. It is a heterogeneous disease, so tumours can have different molecular features and clinical behaviours. Highly metastatic tumours, such as those of the triple-negative subtype, are associated with the worst prognoses. There are limited treatment options for triple negative tumours as they lack the cell surface receptors that are recognized by current therapies, thus there is intense interest in identifying new molecular targets to assess and treat disease. We are studying the ShcD adaptor protein, which functions as a relay within the cell to transmit signals for growth, movement and invasion. We have found increased levels of ShcD in human triple-negative breast cancer, and our preliminary data shows that overexpression of ShcD can promote breast cancer cell invasion and activate signalling pathways that allow tumour cells to migrate, invade and form metastases. This project will investigate how altered ShcD signalling promotes breast tumorigenesis. Our overall goal is to determine whether ShcD could serve as a prognostic indicator and/or target of metastatic disease, and ultimately provide a more precise therapeutic entry point.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
453446
Name
Jones Nina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Investigating the role of ShcD signaling in metastatic breast cancer
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Metastasis; Oncogenes; Suppressors; Tumour; Tumour Progression And Metastasis
Abstract
Breast cancer is the most frequently diagnosed cancer worldwide and it is responsible for more female deaths than any other cancer. It is a heterogeneous disease, so tumours can have different molecular features and clinical behaviours. Highly metastatic tumours, such as those of the triple-negative subtype, are associated with the worst prognoses. There are limited treatment options for triple negative tumours as they lack the cell surface receptors that are recognized by current therapies, thus there is intense interest in identifying new molecular targets to assess and treat disease. We are studying the ShcD adaptor protein, which functions as a relay within the cell to transmit signals for growth, movement and invasion. We have found increased levels of ShcD in human triple-negative breast cancer, and our preliminary data shows that overexpression of ShcD can promote breast cancer cell invasion and activate signalling pathways that allow tumour cells to migrate, invade and form metastases. This project will investigate how altered ShcD signalling promotes breast tumorigenesis. Our overall goal is to determine whether ShcD could serve as a prognostic indicator and/or target of metastatic disease, and ultimately provide a more precise therapeutic entry point.
Competitiondate
202103
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Jones, Nina
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~